Human medicines European public assessment report (EPAR): Ranluspec, ranibizumab, Date of authorisation: 10/02/2026, Status: Authorised
Human medicines European public assessment report (EPAR): Tivdak, tisotumab vedotin, Date of authorisation: 28/03/2025, Revision: 3, Status: Authorised
Human medicines European public assessment report (EPAR): Tepadina, thiotepa, Date of authorisation: 15/03/2010, Revision: 24, Status: Authorised
Agenda - Webinar on the use of platform approaches in the non-clinical and clinical domains
Human medicines European public assessment report (EPAR): Fintepla, fenfluramine, Date of authorisation: 18/12/2020, Revision: 15, Status: Authorised
ICH Q14 Analytical procedure development - Scientific guideline
European Medicines Agency’s data protection notice for the operation of the Security Access Control System
Record of data processing activity relating to Security Access Control System
Product Management Service (PMS) information day 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 9 June 2026, 09:00 (CEST) to 9 June 2026, 13:00 (CEST)
Agenda - PDCO agenda of the 24-27 February 2026 meeting